Compare CYTK & EAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | EAT |
|---|---|---|
| Founded | 1997 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.2B |
| IPO Year | 2004 | 1994 |
| Metric | CYTK | EAT |
|---|---|---|
| Price | $70.05 | $141.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 18 |
| Target Price | $85.59 | ★ $184.41 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 01-01-0001 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.49 | ★ 144.71 |
| EPS | N/A | ★ 5.03 |
| Revenue | $13,368,000.00 | ★ $5,384,200,000.00 |
| Revenue This Year | $341.94 | $8.99 |
| Revenue Next Year | $48.30 | $5.47 |
| P/E Ratio | ★ N/A | $27.93 |
| Revenue Growth | N/A | ★ 21.95 |
| 52 Week Low | $29.31 | $100.30 |
| 52 Week High | $70.98 | $187.12 |
| Indicator | CYTK | EAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 34.18 |
| Support Level | $59.23 | $139.52 |
| Resistance Level | $67.75 | $169.95 |
| Average True Range (ATR) | 2.38 | 7.22 |
| MACD | 0.33 | -3.12 |
| Stochastic Oscillator | 79.93 | 12.96 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.